公开(公告)号：US20200338096A1

公开(公告)日：2020-10-29

申请号：US16758742

申请日：2018-10-17

申请人： Bayer Aktiengesellschaft ,  Bayer Pharma Aktiengesellschaft

发明人： Marie-Pierre COLLIN-KROEPELIN ,  Peter KOLKHOF ,  Thomas NEUBAUER ,  Chantal FUERSTNER ,  Elisabeth POOK ,  Matthias Beat WITTWER ,  Carsten SCHMECK ,  Pierre WASNAIRE ,  Heiko SCHIRMER ,  Hana CERNECKA ,  Karoline DROEBNER ,  Hanna TINEL ,  Anja BUCHMUELLER ,  Thomas MONDRITZKI ,  Axel KRETSCHMER ,  Klemens LUSTIG ,  Robert FRICKE ,  Guillaume LEVILAIN ,  Ursula KRENZ ,  Norbert WITOWSKI

IPC分类号： A61K31/675 ,  A61K45/06 ,  C07F9/6558 ,  A61P13/12

摘要： The present invention relates to prodrugs of 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[3-(trifluoromethyl)-pyridin-2-yl]-1H-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-[2-(trifluoromethyl)-phenyl]-1H-1,2,4-triazole-5-carboxamide and 3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5-dihydro-1H-1,2,4-triazol-1-yl}methyl)-1-(3-chloropyridin-2-yl)-1H-1,2,4-triazole-5-carboxamide, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.